In a nutshell This review looked at SGLT2 inhibitor medications for people with both type 2 diabetes (T2D) and chronic kidney disease (CKD). It found that SGLT2 inhibitors reduced worsening of the kidneys for these patients. Some background For people with diabetes, the body cannot control the amount of glucose (sugar) in the blood without treatment....
Read More
In a nutshell This study looked at the use of sotagliflozin (Zynquista) in patients with poorly controlled type 2 diabetes (T2D) and chronic kidney disease (CKD). It found that patients taking sotagliflozin was associated with a lower risk of heart attack, stroke, or death. Some background Patients with T2D and CKD are...
Read More
In a nutshell This study examined the effect of SGLT2 inhibitors on symptoms of kidney disease in patients with Type 2 diabetes (T2D). The authors found that these agents helped lower the chance of developing kidney disease in these patients. Some background In patients with diabetes, high blood glucose levels can lead to other health...
Read More
In a nutshell This study investigated the safety of Januvia (sitagliptin) in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). They determined that sitagliptin was safe in these patients. Some background CKD is a major complication of T2D. It can lower the quality of life and increase the mortality risk. CKD can also influence...
Read More
In a nutshell The study examined the role blood glucose (sugar) levels and blood glucose variability play in recovery from urinary tract infections in patients with type 2 diabetes plus chronic kidney disease. Some background High blood glucose levels are often a part of type 2 diabetes. One complication from high blood glucose is kidney damage....
Read More
